These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35688991)

  • 1. Joint Disposition Properties and Comprehensive Pharmacokinetic Characterization of Antibody-Drug Conjugates.
    Liao KH; Williams JH; Palani S; Yin D; Meng X
    AAPS J; 2022 Jun; 24(4):73. PubMed ID: 35688991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics.
    Sukumaran S; Zhang C; Leipold DD; Saad OM; Xu K; Gadkar K; Samineni D; Wang B; Milojic-Blair M; Carrasco-Triguero M; Rubinfeld B; Fielder P; Lin K; Ramanujan S
    AAPS J; 2017 Jan; 19(1):130-140. PubMed ID: 27679517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic considerations for antibody drug conjugates.
    Lin K; Tibbitts J
    Pharm Res; 2012 Sep; 29(9):2354-66. PubMed ID: 22740180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Properties of Cysteine-Conjugated Antibody-Drug Conjugates Are Impacted by the IgG Subclass.
    Datta-Mannan A; Choi H; Stokell D; Tang J; Murphy A; Wrobleski A; Feng Y
    AAPS J; 2018 Sep; 20(6):103. PubMed ID: 30255287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a generalized pharmacokinetic model to characterize clinical pharmacokinetics of monomethyl auristatin E-based antibody-drug conjugates.
    Chang HP; Cheung YK; Liu S; Shah DK
    Br J Clin Pharmacol; 2024 Jul; 90(7):1637-1655. PubMed ID: 38566392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes.
    Drake PM; Albers AE; Baker J; Banas S; Barfield RM; Bhat AS; de Hart GW; Garofalo AW; Holder P; Jones LC; Kudirka R; McFarland J; Zmolek W; Rabuka D
    Bioconjug Chem; 2014 Jul; 25(7):1331-41. PubMed ID: 24924618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Method development of a novel PK assay for antibody-conjugated drug measurement of ADCs using peptide-linker drug analyte.
    Hyung SJ; Li D; Koppada N; Kaur S; Saad OM
    Anal Bioanal Chem; 2019 May; 411(12):2587-2596. PubMed ID: 30828756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
    Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
    Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
    Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
    PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catabolism of antibody drug conjugates and characterization methods.
    Shadid M; Bowlin S; Bolleddula J
    Bioorg Med Chem; 2017 Jun; 25(12):2933-2945. PubMed ID: 28438386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.
    Kågedal M; Gibiansky L; Xu J; Wang X; Samineni D; Chen SC; Lu D; Agarwal P; Wang B; Saad O; Koppada N; Fine BM; Jin JY; Girish S; Li C
    J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):537-548. PubMed ID: 28918591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of drug-to-antibody ratio of antibody-drug conjugate in biological samples using microflow-liquid chromatography/high-resolution mass spectrometry.
    Inoue K; Mochizuki T; Kasamori N; Komori T
    Bioanalysis; 2022 Dec; 14(24):1533-1545. PubMed ID: 36825963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.
    Malik P; Phipps C; Edginton A; Blay J
    Pharm Res; 2017 Dec; 34(12):2579-2595. PubMed ID: 28924691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates.
    Ait-Oudhia S; Zhang W; Mager DE
    AAPS J; 2017 Sep; 19(5):1436-1448. PubMed ID: 28646408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues.
    Zhang D; Dragovich PS; Yu SF; Ma Y; Pillow TH; Sadowsky JD; Su D; Wang W; Polson A; Khojasteh SC; Hop CECA
    Drug Metab Dispos; 2019 Oct; 47(10):1146-1155. PubMed ID: 31358513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates.
    Pabst M; McDowell W; Manin A; Kyle A; Camper N; De Juan E; Parekh V; Rudge F; Makwana H; Kantner T; Parekh H; Michelet A; Sheng X; Popa G; Tucker C; Khayrzad F; Pollard D; Kozakowska K; Resende R; Jenkins A; Simoes F; Morris D; Williams P; Badescu G; Baker MP; Bird M; Frigerio M; Godwin A
    J Control Release; 2017 May; 253():160-164. PubMed ID: 28257988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin.
    Shah DK; Haddish-Berhane N; Betts A
    J Pharmacokinet Pharmacodyn; 2012 Dec; 39(6):643-59. PubMed ID: 23151991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-Based Pharmacokinetic and Drug-Drug Interaction Characterization of Antibody-Drug Conjugates in Oncology Clinical Development: An International Consortium for Innovation and Quality in Pharmaceutical Development Perspective.
    Li C; Menon R; Walles M; Singh R; Upreti VV; Brackman D; Lee AJ; Endres CJ; Kumar S; Zhang D; Barletta F; Suri A; Hainzl D; Liao KH; Lalovic B; Beaumont M; Zuo P; Mayer AP; Wei D
    Clin Pharmacol Ther; 2022 Oct; 112(4):754-769. PubMed ID: 34657311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacology of vc-MMAE antibody-drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies.
    Li C; Zhang C; Li Z; Samineni D; Lu D; Wang B; Chen SC; Zhang R; Agarwal P; Fine BM; Girish S
    MAbs; 2020; 12(1):1699768. PubMed ID: 31852341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capturing the Magic Bullet: Pharmacokinetic Principles and Modeling of Antibody-Drug Conjugates.
    Zuo P
    AAPS J; 2020 Aug; 22(5):105. PubMed ID: 32767003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.